These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25296234)

  • 41. A systematic review of the use of rituximab as induction therapy in renal transplantation.
    Macklin PS; Morris PJ; Knight SR
    Transplant Rev (Orlando); 2015 Apr; 29(2):103-8. PubMed ID: 25555541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding kidney transplant patients' treatment choices: The interaction of emotion with medical and social influences on risk preferences.
    Harrington J; Morgan M
    Soc Sci Med; 2016 Apr; 155():43-50. PubMed ID: 26986241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Editorial Comment to Low-dose rituximab induction therapy is effective in immunological high-risk renal transplantation without increasing cytomegalovirus infection.
    Kobayashi T
    Int J Urol; 2020 Dec; 27(12):1142-1143. PubMed ID: 33012075
    [No Abstract]   [Full Text] [Related]  

  • 44. Induction Therapy, HLA Mismatching, and Standard-Risk Kidney Transplantation.
    Nassar M; Elshafey M; Gonzalez C; Nso N; Mahdi M; Elsayed I
    Am J Nephrol; 2021; 52(8):691. PubMed ID: 34515034
    [No Abstract]   [Full Text] [Related]  

  • 45. Review: immunosuppression for the lung transplant patient.
    Kotecha S; Ivulich S; Snell G
    J Thorac Dis; 2021 Nov; 13(11):6628-6644. PubMed ID: 34992841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction Therapy in Immunologically Well-Matched Recipients: Less May Be More.
    Potluri VS; Bloom RD
    Clin J Am Soc Nephrol; 2022 Feb; 17(2):173-175. PubMed ID: 35131923
    [No Abstract]   [Full Text] [Related]  

  • 47. Assessing pharmacologic and nonpharmacologic risks in candidates for kidney transplantation.
    Maldonado AQ; Tichy EM; Rogers CC; Campara M; Ensor C; Doligalski CT; Gabardi S; Descourouez JL; Doyle IC; Trofe-Clark J
    Am J Health Syst Pharm; 2015 May; 72(10):781-93. PubMed ID: 25941253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial immunosuppression and managing rejection.
    Fuehner T; Benden C; Gottlieb J
    Intensive Care Med; 2019 Mar; 45(3):388-390. PubMed ID: 30877321
    [No Abstract]   [Full Text] [Related]  

  • 49. [Care of the adult kidney transplant recipient].
    Habicht A; Stangl M
    MMW Fortschr Med; 2016 Nov; 158(20):64-72. PubMed ID: 27844359
    [No Abstract]   [Full Text] [Related]  

  • 50. Current practices: immunosuppression induction, maintenance and rejection regimens in 213 consecutive transplant recipients.
    Gass A; Eisen H; Griffith B; Kobashigawa J; Koerner M; Mancini D; Mehra M; Meiser B; Webber S; Young J; Gilb E; Tuteja S
    J Heart Lung Transplant; 2001 Feb; 20(2):162. PubMed ID: 11250243
    [No Abstract]   [Full Text] [Related]  

  • 51. Induction.
    Smith BR
    Anesthesiology; 2022 Oct; 137(4):511-513. PubMed ID: 35727085
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical transplantation and tolerance: are we there yet?
    Saidi RF; Hejazii Kenari SK
    Int J Organ Transplant Med; 2014; 5(4):137-45. PubMed ID: 25426282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis.
    Zhao L; Hu C; Han F; Chen D; Cheng J; Wu J; Peng W; Chen J
    Stem Cell Res Ther; 2021 Mar; 12(1):158. PubMed ID: 33648596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
    Blomberg M; He SY; Harwood C; Arron ST; Demehri S; Green A; Asgari MM;
    Br J Dermatol; 2017 Nov; 177(5):1225-1233. PubMed ID: 29086412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction therapy in renal transplant recipients: a review.
    Laftavi MR; Sharma R; Feng L; Said M; Pankewycz O
    Immunol Invest; 2014; 43(8):790-806. PubMed ID: 25296234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of clinical association and effect of peripheral WBC counts on immune cell function test in kidney transplant recipients with T-cell depleting induction and steroid-sparing maintenance therapy.
    Sageshima J; Ciancio G; Chen L; Dohi T; El-Hinnawi A; Paloyo S; Gaynor JJ; Mattiazzi A; Guerra G; Kupin W; Roth D; Ruiz P; Burke GW
    Transpl Immunol; 2014 Mar; 30(2-3):88-92. PubMed ID: 24518158
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is induction therapy still needed in heart transplantation?
    Aliabadi A; Grömmer M; Zuckermann A
    Curr Opin Organ Transplant; 2011 Oct; 16(5):536-42. PubMed ID: 21836518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The UNOS Scientific Renal Transplant Registry--ten years of kidney transplants.
    Cecka JM
    Clin Transpl; 1997; ():1-14. PubMed ID: 9919387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective.
    Stratta RJ; Farney AC; Rogers J; Orlando G
    Expert Rev Clin Immunol; 2014 Jan; 10(1):117-32. PubMed ID: 24236648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.